GSK - Ticker AI Digest

GSK plc 📰 2
TradingFloor AI GO VIP Login
Important AI Risk Notice

Charts, catalyst summaries, AI scores, forecasts and price context are AI-driven and can hallucinate, lag or miss market-changing information.

Not investment advice. Markets can move fast and any trade or allocation decision remains your responsibility.
AI can hallucinate. Summaries, rankings, forecasts and commentary can be wrong, incomplete or misleading.
AI-driven data only. Signals, dates, prices, sentiment and automation outputs may be delayed, estimated or stale.
Always verify externally. Confirm prices, filings, broker notes and trade setup details with independent sources before acting.
Mobile Command Deck
GSK plc in one cleaner mobile flow.
Tap straight into the module you want. No sideways tab hunt, just a clean route into charts, news, crunch, and the deeper desks.
GSK Data 2026-03-02 Preview Mode
Core Deck
Deep Dive Modules

Digested News

Today's Catalysts (GSK) 2
GSK 14:01
GSK plc
Total Voting Rights
GSK 06:01
GSK plc
Transaction in Own Shares
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 1
GSK 06:01
GSK plc
GSK enters agreement to acquire 35Pharma
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GSK plc announced on February 25, 2026, that it has entered into an agreement to acquire 35Pharma Inc., a Canadian clinical-stage biopharmaceutical company, for $950 million in cash. The acquisition includes HS235, a potentially best-in-class activin signaling inhibitor in clinical development for treating cardiopulmonary diseases, particularly pulmonary hypertension (PH). HS235 offers a differentiated profile by reducing the risk of bleeding and providing metabolic benefits, addressing key limitations of current PH therapies. The drug has completed Phase I trials and is set to begin studies in pulmonary arterial hypertension (PAH) and PH due to heart failure with preserved ejection fraction (PH-HFpEF).
PH affects approximately 82 million people globally, with limited treatment options and a five-year survival rate of around 50%. The global PH therapies market is projected to reach $18 billion by 2032, with activin signaling inhibitors expected to account for 50%. HS235’s mechanism targets the activin receptor pathway, reducing adverse events associated with current treatments, and offers additional metabolic benefits such as fat-selective weight loss and improved insulin sensitivity.
The acquisition strengthens GSK’s Respiratory, Immunology, and Inflammation (RI&I) portfolio, providing scalable opportunities to address metabolic, inflammatory, vascular, and fibrotic drivers of chronic diseases affecting the lung, liver, and kidney. The transaction is subject to regulatory approvals in the US and Canada and is expected to close pending customary conditions.
Agreement
Approvals 2
GSK 06:01
GSK plc
Exdensur approved by the European Commission
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
* **The Evolution of the InternetA Journey Through Time**
The internet has undergone a remarkable transformation since its inception. Initially conceived as a tool for academic and military communication, it has evolved into a global phenomenon that connects billions of people across the world. This evolution can be traced through several key phases
1. **The Early Days (1960s-1980s)**
**ARPANET and the Birth of the Internet**
The Advanced Research Projects Agency Network (ARPANET) was one of the earliest packet-switching networks, funded by the U.S. Department of Defense. It laid the foundation for what would become the modern internet.
**Email and the World Wide Web**
In the 1970s, email emerged as a revolutionary communication tool, allowing users to exchange messages across the network. The World Wide Web (WWW) followed in the late 1980s, introducing hypertext and a graphical interface that made information more accessible.
2. **The Dot-Com Boom (1990s-2000s)**
**Commercialization and the Rise of ISPs**
The 1990s saw the commercialization of the internet with the rise of Internet Service Providers (ISPs). Companies like AOL and CompuServe brought the internet to the masses, though access was often limited and content was curated.
**The Open Web and Blogging**
The late 1990s and early 2000s witnessed the emergence of the open web, with the rise of blogs and content management systems like WordPress. This democratized content creation, allowing anyone to publish their thoughts online.
3. **The Social Media Era (2000s-Present):**
**Web 2.0 and User-Generated Content**
The 2000s introduced Web 2.0, characterized by interactive and dynamic content. Platforms like Facebook, Twitter, and YouTube empowered users to create and share content, transforming the internet into a social media hub.
**Mobile Revolution**
The proliferation of smartphones and mobile internet access has made the web an integral part of daily life, accessible anytime and anywhere.
**Conclusion**
The internets evolution from a military project to a global social phenomenon reflects humanitys innate desire to connect, communicate, and share. It continues to shape our world, influencing everything from commerce to culture, and its impact only grows more profound with each passing day.
Approvals
GSK 06:01
GSK plc
Nucala COPD approved by the European Commission
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GSK plc announced on February 6, 2026, that the European Commission has approved **Nucala (mepolizumab)**, a monoclonal antibody targeting interleukin-5 (IL-5), as an add-on maintenance treatment for **uncontrolled chronic obstructive pulmonary disease (COPD)** in adults with raised blood eosinophils. This approval is based on positive results from the **MATINEE phase III trial**, which demonstrated a significant reduction in moderate/severe exacerbations compared to placebo in patients receiving standard inhaled triple therapy. Nucala is the **first and only monthly biologic** in the EU evaluated for a wide COPD population with an eosinophilic phenotype, addressing a critical need for patients who experience persistent symptoms and exacerbations despite current treatments.
Key highlights include
**Clinical Efficacy** MATINEE showed a 21% reduction in annualized exacerbation rates (0.80 vs. 1.01 per year) and a 35% reduction in exacerbations leading to emergency department visits or hospitalizations.
**Patient Impact** COPD affects over 390 million people globally, with high hospitalization and mortality rates. Nucala offers a new option to reduce exacerbations, which can cause irreversible lung damage and hospitalizations.
**Safety Profile** Adverse events were similar between Nucala and placebo groups.
**Broader Approvals** Nucala is already approved in Europe for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES), and for COPD in the US, UK, and China.
This approval marks a significant advancement in COPD treatment, providing relief for millions of Europeans with uncontrolled disease and highlighting GSK’s commitment to respiratory innovation.
Approvals
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 1
GSK 06:01
GSK plc
GSK - fourth tranche of share buyback programme
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSK plc announced the commencement of the fourth tranche of its £2 billion share buyback programme, valued at up to £0.45 billion, on February 17, 2026. This tranche, part of a broader programme initiated in February 2025, aims to return excess capital to shareholders, reduce share capital, and enhance earnings per share. The purchases, executed through a non-discretionary agreement with BNP Paribas S.A., are expected to be completed by April 24, 2026, and will be conducted in compliance with UK and EU regulations. The shares purchased will be held as Treasury shares, and no repurchases will be made in the United States or for American Depositary Receipts. The programme operates within the parameters of GSKs general authority to repurchase shares, as granted at its 2025 Annual General Meeting.
BuyBack
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 18
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 15:55
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of 3,334 Ordinary Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 09:31
GSK plc
Director/PDMR Shareholding
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of 2,500 Ordinary Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 0
No items for this category on selected date.
Litigation 0
No items for this category on selected date.
NewContract 0
No items for this category on selected date.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 0
No items for this category on selected date.
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
GSK 06:01
GSK plc
Final Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSK PLC has released its final results for 2025, reporting strong performance driven by Specialty Medicines. Key highlights include
Total sales of £32.7 billion, up 4% AER and 7% CER, with Specialty Medicines sales growing 17% to £13.5 billion.
Respiratory, Immunology & Inflammation sales increased 18% to £3.8 billion, Oncology grew 43% to £2.0 billion, and HIV sales rose 11% to £7.7 billion.
Vaccines sales were up 2% to £9.2 billion, led by Shingrix at £3.6 billion (+8%).
Total operating profit increased over 100% and EPS grew over 100%, driven by lower legal expenses, CCL charges and higher operating income.
Core operating profit grew 11% and Core EPS increased 12%, reflecting Specialty Medicines and Vaccines growth.
Cash generated from operations was £8.9 billion with free cash flow of £4.0 billion.
The company reaffirmed its 2026 guidance, expecting 3-5% turnover growth, 7-9% Core operating profit growth, and 7-9% Core EPS growth.
GSK also reiterated its 2031 sales outlook of over £40 billion.
The strong performance was driven by Specialty Medicines, particularly in Respiratory, Immunology & Inflammation, Oncology and HIV. R&D momentum continued with 5 major FDA approvals and pipeline progress. GSK expects this positive momentum to continue in 2026, focused on commercial launches and R&D acceleration. The company remains committed to shareholder returns through dividends and share buybacks. Overall, GSK delivered robust 2025 results and reaffirmed its long-term outlook.
Here is an HTML table comparing the year-on-year financials and debt for GSK PLC based on the provided text:
Metric20242025Change
Total Sales (£ billion)31.432.7+4% AER; +7% CER
Specialty Medicines Sales (£ billion)12.113.5+17% CER
Vaccines Sales (£ billion)9.19.2+2% CER
General Medicines Sales (£ billion)10.210.0-1% CER
Total Operating Profit (£ billion)4.07.9>100% CER
Core Operating Profit (£ billion)9.19.8+11% CER
Total EPS (pence)63.2141.1>100% CER
Core EPS (pence)159.3172.0+12% CER
Cash Generated from Operations (£ billion)7.98.9+14% CER
Free Cash Flow (£ billion)2.94.0+41% CER
Total Net Debt (£ billion)13.114.5+11% CER
**Notes:** * **AER**: Actual Exchange Rate * **CER**: Constant Exchange Rate * **EPS**: Earnings Per Share This table provides a snapshot of GSK's financial performance and debt position, highlighting key metrics and their year-on-year changes.
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 0
No items for this category on selected date.
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 37
GSK 14:01
GSK plc
Total Voting Rights
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:06
GSK plc
Linerixibat accepted for priority review in China
GSK 06:01
GSK plc
Bepirovirsen accepted for Japan regulatory review
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 15:55
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
GSK enters agreement to acquire 35Pharma
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GSK plc announced on February 25, 2026, that it has entered into an agreement to acquire 35Pharma Inc., a Canadian clinical-stage biopharmaceutical company, for $950 million in cash. The acquisition includes HS235, a potentially best-in-class activin signaling inhibitor in clinical development for treating cardiopulmonary diseases, particularly pulmonary hypertension (PH). HS235 offers a differentiated profile by reducing the risk of bleeding and providing metabolic benefits, addressing key limitations of current PH therapies. The drug has completed Phase I trials and is set to begin studies in pulmonary arterial hypertension (PAH) and PH due to heart failure with preserved ejection fraction (PH-HFpEF).
PH affects approximately 82 million people globally, with limited treatment options and a five-year survival rate of around 50%. The global PH therapies market is projected to reach $18 billion by 2032, with activin signaling inhibitors expected to account for 50%. HS235’s mechanism targets the activin receptor pathway, reducing adverse events associated with current treatments, and offers additional metabolic benefits such as fat-selective weight loss and improved insulin sensitivity.
The acquisition strengthens GSK’s Respiratory, Immunology, and Inflammation (RI&I) portfolio, providing scalable opportunities to address metabolic, inflammatory, vascular, and fibrotic drivers of chronic diseases affecting the lung, liver, and kidney. The transaction is subject to regulatory approvals in the US and Canada and is expected to close pending customary conditions.
Agreement
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of 3,334 Ordinary Shares
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 06:01
GSK plc
Transaction in Own Shares
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
GSK - fourth tranche of share buyback programme
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSK plc announced the commencement of the fourth tranche of its £2 billion share buyback programme, valued at up to £0.45 billion, on February 17, 2026. This tranche, part of a broader programme initiated in February 2025, aims to return excess capital to shareholders, reduce share capital, and enhance earnings per share. The purchases, executed through a non-discretionary agreement with BNP Paribas S.A., are expected to be completed by April 24, 2026, and will be conducted in compliance with UK and EU regulations. The shares purchased will be held as Treasury shares, and no repurchases will be made in the United States or for American Depositary Receipts. The programme operates within the parameters of GSKs general authority to repurchase shares, as granted at its 2025 Annual General Meeting.
BuyBack
GSK 06:01
GSK plc
Exdensur approved by the European Commission
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
* **The Evolution of the InternetA Journey Through Time**
The internet has undergone a remarkable transformation since its inception. Initially conceived as a tool for academic and military communication, it has evolved into a global phenomenon that connects billions of people across the world. This evolution can be traced through several key phases
1. **The Early Days (1960s-1980s)**
**ARPANET and the Birth of the Internet**
The Advanced Research Projects Agency Network (ARPANET) was one of the earliest packet-switching networks, funded by the U.S. Department of Defense. It laid the foundation for what would become the modern internet.
**Email and the World Wide Web**
In the 1970s, email emerged as a revolutionary communication tool, allowing users to exchange messages across the network. The World Wide Web (WWW) followed in the late 1980s, introducing hypertext and a graphical interface that made information more accessible.
2. **The Dot-Com Boom (1990s-2000s)**
**Commercialization and the Rise of ISPs**
The 1990s saw the commercialization of the internet with the rise of Internet Service Providers (ISPs). Companies like AOL and CompuServe brought the internet to the masses, though access was often limited and content was curated.
**The Open Web and Blogging**
The late 1990s and early 2000s witnessed the emergence of the open web, with the rise of blogs and content management systems like WordPress. This democratized content creation, allowing anyone to publish their thoughts online.
3. **The Social Media Era (2000s-Present):**
**Web 2.0 and User-Generated Content**
The 2000s introduced Web 2.0, characterized by interactive and dynamic content. Platforms like Facebook, Twitter, and YouTube empowered users to create and share content, transforming the internet into a social media hub.
**Mobile Revolution**
The proliferation of smartphones and mobile internet access has made the web an integral part of daily life, accessible anytime and anywhere.
**Conclusion**
The internets evolution from a military project to a global social phenomenon reflects humanitys innate desire to connect, communicate, and share. It continues to shape our world, influencing everything from commerce to culture, and its impact only grows more profound with each passing day.
Approvals
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
China CDE accepts Arexvy adults 60+ application
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 09:31
GSK plc
Director/PDMR Shareholding
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
<mark style="background-coloryellow">Purchase</mark> of 2,500 Ordinary Shares
GSK 06:01
GSK plc
Nucala COPD approved by the European Commission
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
GSK plc announced on February 6, 2026, that the European Commission has approved **Nucala (mepolizumab)**, a monoclonal antibody targeting interleukin-5 (IL-5), as an add-on maintenance treatment for **uncontrolled chronic obstructive pulmonary disease (COPD)** in adults with raised blood eosinophils. This approval is based on positive results from the **MATINEE phase III trial**, which demonstrated a significant reduction in moderate/severe exacerbations compared to placebo in patients receiving standard inhaled triple therapy. Nucala is the **first and only monthly biologic** in the EU evaluated for a wide COPD population with an eosinophilic phenotype, addressing a critical need for patients who experience persistent symptoms and exacerbations despite current treatments.
Key highlights include
**Clinical Efficacy** MATINEE showed a 21% reduction in annualized exacerbation rates (0.80 vs. 1.01 per year) and a 35% reduction in exacerbations leading to emergency department visits or hospitalizations.
**Patient Impact** COPD affects over 390 million people globally, with high hospitalization and mortality rates. Nucala offers a new option to reduce exacerbations, which can cause irreversible lung damage and hospitalizations.
**Safety Profile** Adverse events were similar between Nucala and placebo groups.
**Broader Approvals** Nucala is already approved in Europe for severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES), and for COPD in the US, UK, and China.
This approval marks a significant advancement in COPD treatment, providing relief for millions of Europeans with uncontrolled disease and highlighting GSK’s commitment to respiratory innovation.
Approvals
GSK 14:31
GSK plc
Director/PDMR Shareholding
GSK 06:01
GSK plc
Final Results
AI Expand: Explanation + Tables
Return to today’s catalyst cards, chart beacons and AI charts.
GSK PLC has released its final results for 2025, reporting strong performance driven by Specialty Medicines. Key highlights include
Total sales of £32.7 billion, up 4% AER and 7% CER, with Specialty Medicines sales growing 17% to £13.5 billion.
Respiratory, Immunology & Inflammation sales increased 18% to £3.8 billion, Oncology grew 43% to £2.0 billion, and HIV sales rose 11% to £7.7 billion.
Vaccines sales were up 2% to £9.2 billion, led by Shingrix at £3.6 billion (+8%).
Total operating profit increased over 100% and EPS grew over 100%, driven by lower legal expenses, CCL charges and higher operating income.
Core operating profit grew 11% and Core EPS increased 12%, reflecting Specialty Medicines and Vaccines growth.
Cash generated from operations was £8.9 billion with free cash flow of £4.0 billion.
The company reaffirmed its 2026 guidance, expecting 3-5% turnover growth, 7-9% Core operating profit growth, and 7-9% Core EPS growth.
GSK also reiterated its 2031 sales outlook of over £40 billion.
The strong performance was driven by Specialty Medicines, particularly in Respiratory, Immunology & Inflammation, Oncology and HIV. R&D momentum continued with 5 major FDA approvals and pipeline progress. GSK expects this positive momentum to continue in 2026, focused on commercial launches and R&D acceleration. The company remains committed to shareholder returns through dividends and share buybacks. Overall, GSK delivered robust 2025 results and reaffirmed its long-term outlook.
Here is an HTML table comparing the year-on-year financials and debt for GSK PLC based on the provided text:
Metric20242025Change
Total Sales (£ billion)31.432.7+4% AER; +7% CER
Specialty Medicines Sales (£ billion)12.113.5+17% CER
Vaccines Sales (£ billion)9.19.2+2% CER
General Medicines Sales (£ billion)10.210.0-1% CER
Total Operating Profit (£ billion)4.07.9>100% CER
Core Operating Profit (£ billion)9.19.8+11% CER
Total EPS (pence)63.2141.1>100% CER
Core EPS (pence)159.3172.0+12% CER
Cash Generated from Operations (£ billion)7.98.9+14% CER
Free Cash Flow (£ billion)2.94.0+41% CER
Total Net Debt (£ billion)13.114.5+11% CER
**Notes:** * **AER**: Actual Exchange Rate * **CER**: Constant Exchange Rate * **EPS**: Earnings Per Share This table provides a snapshot of GSK's financial performance and debt position, highlighting key metrics and their year-on-year changes.
GSK 14:01
GSK plc
Total Voting Rights

AI Crunch

Single-Ticker AI Crunch
GSK signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for GSK plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full GSK AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for GSK on 2026-03-02.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
85.6B
Enterprise Value
70.0B
Public Float
97.2
Broker Target
2048.5
Shares Out
4.0B
Long Interest
96
Short Interest
4
Exchange
LSE
Currency Code
GBX
ISIN
GB00BN7SWP63
Market
LSE - MAIN MARKET
Sector
Pharmaceuticals and Biotechnology
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

News And Alerts First

2 live alerts now opens the financials desk for GSK.

Start with the headline flow and alert tape first. Then drop straight into Financial Forecastist below for the revenue path, EPS shape, cash pressure and balance-sheet read while the catalyst context is still hot.
Live Alerts Data 2026-03-02 Forecastist Below
Read the alert tape first, then move into Financial Forecastist below. Use AI Expand on any catalyst card to open the AI explanation and results tables without losing the ticker context.
2 Alerts
Front Of Desk
GSK plc has fresh filing flow live now, so the tape is framing the revenue, leverage and valuation story below.
14:01 Today's Alert Total Voting Rights 06:01 Today's Alert Transaction in Own Shares
Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
0.72
Ex Divi
2026-02-19
Earnings Date
2026-04-28
Net Debt
14.3B
Cash
3.4B
EPS
1.39
Net Income
5.7B
Revenue
32.7B
Enterprise Value
70.0B
Trailing PE
15.4245
Forward PE
22.4719
Price Sales TTM
2.6211
Price Book MRQ
5.2286
EV Revenue
3.067
EV EBITDA
9.6318
Financial Forecastist

Mixed financial engine

Revenue is accelerating +6.2% against the prior comparable period. Net margin is expanding by 2.3 pts. Net debt is building +7.8%.

Revenue +6.2% Net Income +53.6% FCF +27.1% Current Ratio 0.82x Forward Rev 8.4B
Mixed
Quarter Revenue
8.6B
+6.2%
vs prior comparable quarter
Net Margin
+7.4%
+2.3 pts
profitability pulse
Free Cash Flow
1.5B
+27.1%
cash conversion
Net Debt / EBITDA
6.5x
+7.8%
lower is cleaner
Revenue Engine

Latest quarter printed 8.6B with the top line pushing higher against the last comparable period.

Profit Stack

Net income landed at 636.0M and the margin profile is broadening. That usually tells us whether operating leverage is finally kicking in.

Balance-Sheet Pressure

Cash sits near 3.4B while net debt is 14.3B. The leverage stack is moving the wrong way.

Quarterly Revenue Runway

Actual revenue bars, consensus revenue where available, plus the terminal model path.

Profit And Cash Conversion

Net income and free cash flow moving together is usually what separates genuine improvement from noise.

Balance-Sheet Pressure

Cash, net debt and liquidity tell us whether the business is strengthening or just surviving.

Annual Power Curve

Longer-cycle revenue and net income help frame whether the company is compounding or rolling over.
Q2 2025
Consensus
7.8B
Revenue Path
0.42
EPS / Earnings
Growth cue -0.0%
Q3 2025
Consensus
8.3B
Revenue Path
0.47
EPS / Earnings
Growth cue -0.1%
Q1 2026
Consensus
7.6B
Revenue Path
0.45
EPS / Earnings
Growth cue -0.0%
Q2 2026
Consensus
8.4B
Revenue Path
0.49
EPS / Earnings
Growth cue +0.0%
FY 2026
Consensus
34.0B
Revenue Path
1.80
EPS / Earnings
Growth cue +0.0%
FY 2027
Consensus
35.6B
Revenue Path
1.96
EPS / Earnings
Growth cue +0.1%

Quarterly Statement Tape

Last 6 Quarters
Period Revenue Net Income FCF Net Debt
Q4 2025 8.6B 636.0M 1.5B 14.3B
Q3 2025 8.5B 2.0B 1.3B 14.5B
Q2 2025 8.0B 1.4B 1.5B 13.8B
Q1 2025 7.5B 1.6B 697.0M 14.0B
Q4 2024 8.1B 414.0M 1.2B 13.3B
Q3 2024 8.0B -58.0M 1.8B 12.9B

Annual Financial Power

Last 5 Years
Period Revenue Net Income EBITDA FCF
FY 2025 32.7B 5.7B 11.9B 6.0B
FY 2024 31.4B 2.6B 6.7B 3.6B
FY 2023 30.3B 4.9B 9.1B 4.4B
FY 2022 29.3B 15.0B 8.6B 5.1B
FY 2021 24.7B 4.4B 6.5B 5.0B

Structure DNA

Market Structure DNA

Yield Compounder profile with trend runway open

Price is 87.9% through the 52-week range, +1.5% vs 50DMA and +21.1% vs 200DMA. 48.4% of the register is locked by institutions and insiders, leaving 51.6% free float. Capital rhythm reads quarterly with forward yield near 3.4% and payout around 38.3%.

Trend runway open Institutional gravity Reliable income rhythm As Of 2026-04-19
Yield Compounder
Structure Score
77.1 / 100
Yield Compounder
Trend Stack
+1.5% / +21.1%
vs 50DMA / 200DMA
52W Position
87.9%
auction position inside the yearly range
Ownership Lock
48.4%
46.7% institutions | 1.7% insiders
Pressure Pocket
51.6% free float
Vendor short-float fields were not supplied
Capital Rhythm
Quarterly
Yield 3.4% | payout 38.3%
Trend Runway

Implied spot is 2,144.18 with the stock +1.5% vs 50DMA and +21.1% vs 200DMA. The tape is sitting 87.9% through the 52-week range, which frames the regime as trend runway open.

Ownership Register

Institutions hold about 46.7% and insiders about 1.7%, locking roughly 48.4% of the register and leaving 51.6% in free float. That reads as institutional gravity.

Pressure Pocket

The API did not return a usable short-float field for this ticker, so the pressure score leans more on float lock and crowding than a full short ledger.

Capital Rhythm

Dividend cadence reads quarterly with 4 event(s) in the last full year, a five-year average of 4.0, and stability score 100.0/100. Forward yield sits near 3.4% while payout is around 38.3%.

Structure Score

One-glance gauge for the current market-structure regime.

Pillar Radar

Trend, ownership, pressure, and capital rhythm mapped on one wheel.

Position And Float Balance

Shows whether the stock is extended, tightly held, or carrying capital-return support.

Dividend Cadence Tape

Historical dividend-event counts help reveal how dependable the income rhythm has been.

Dividend Cadence Ledger

Quarterly
Year Dividend Count Context
2026 1 Current partial year
2025 4 Full year
2024 4 Full year
2023 4 Full year
2022 4 Full year
2021 4 Full year
2020 4 Full year
2019 4 Full year

Structure Facts

Live Snapshot
Implied Spot
2,144.18
derived from market cap / shares
52W High
2,265.00
upper auction edge
52W Low
1,267.16
lower auction edge
Beta
0.35
volatility character
Shares Out
4.0B
fully diluted count
Shares Float
3.9B
tradable register
Shares Short
0
borrowed stock
Short Ratio
0.0x
days-to-cover style read
Ex-Dividend
2026-02-19
-59 day(s) to ex-date
Dividend Pay
-
payment date not supplied
Last Split
4:5
2022-07-19

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
3993576204
Public Hands
97.21
Institutions
-
Institutions As Of
-
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
11
Sale Director Dealing
18
Purchase TR1
0
Sale TR1
0
Broker Coverage Rows
40
Institution Holders Tracked
0
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

News And Alerts First

The alert tape opens the door for GSK, and AI Charts sits just below.

Start with the headline flow and live catalyst tape first. Then move straight into AI Charts below for price reaction, AI targets, chart structure and catalyst beacons while the news context is still hot.
Live Tape Data 2026-03-02 AI Charts Below
Read the alert tape first, then move into AI Charts below. Use AI Expand on any catalyst card to open the AI explanation and results tables instantly.
2 Today
Catalyst Pulse
GSK plc has fresh news flow live now, so the tape is framing the chart workspace below.
14:01 Today's Catalyst Total Voting Rights 06:01 Today's Catalyst Transaction in Own Shares
AI Charts Studio
GSK Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2026-03-02 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast 2.64%
RSI Gauge
Price Change
AI Forecast